IBDEI06E ; ; 12-MAY-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 12, 2016
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,6237,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6237,1,3,0)
 ;;=3^Rapidly progr neph synd w/ unsp morphologic changes
 ;;^UTILITY(U,$J,358.3,6237,1,4,0)
 ;;=4^N01.9
 ;;^UTILITY(U,$J,358.3,6237,2)
 ;;=^5015510
 ;;^UTILITY(U,$J,358.3,6238,0)
 ;;=N02.0^^39^446^80
 ;;^UTILITY(U,$J,358.3,6238,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6238,1,3,0)
 ;;=3^Recurrent & perst hematur w/ minor glomerular abnlt
 ;;^UTILITY(U,$J,358.3,6238,1,4,0)
 ;;=4^N02.0
 ;;^UTILITY(U,$J,358.3,6238,2)
 ;;=^5015511
 ;;^UTILITY(U,$J,358.3,6239,0)
 ;;=N02.1^^39^446^79
 ;;^UTILITY(U,$J,358.3,6239,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6239,1,3,0)
 ;;=3^Recurrent & perst hematur w/ focal & seg glomerular lesions
 ;;^UTILITY(U,$J,358.3,6239,1,4,0)
 ;;=4^N02.1
 ;;^UTILITY(U,$J,358.3,6239,2)
 ;;=^5015512
 ;;^UTILITY(U,$J,358.3,6240,0)
 ;;=N02.2^^39^446^77
 ;;^UTILITY(U,$J,358.3,6240,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6240,1,3,0)
 ;;=3^Recurrent & perst hematur w/ diffuse membranous glomrlneph
 ;;^UTILITY(U,$J,358.3,6240,1,4,0)
 ;;=4^N02.2
 ;;^UTILITY(U,$J,358.3,6240,2)
 ;;=^5015513
 ;;^UTILITY(U,$J,358.3,6241,0)
 ;;=N02.3^^39^446^74
 ;;^UTILITY(U,$J,358.3,6241,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6241,1,3,0)
 ;;=3^Recur & perst hematur w/ diffus mesangial prolif glomrlneph
 ;;^UTILITY(U,$J,358.3,6241,1,4,0)
 ;;=4^N02.3
 ;;^UTILITY(U,$J,358.3,6241,2)
 ;;=^5015514
 ;;^UTILITY(U,$J,358.3,6242,0)
 ;;=N02.4^^39^446^73
 ;;^UTILITY(U,$J,358.3,6242,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6242,1,3,0)
 ;;=3^Recur & perst hematur w/ diffus endocaplry prolif glomrlneph
 ;;^UTILITY(U,$J,358.3,6242,1,4,0)
 ;;=4^N02.4
 ;;^UTILITY(U,$J,358.3,6242,2)
 ;;=^5015515
 ;;^UTILITY(U,$J,358.3,6243,0)
 ;;=N02.5^^39^446^78
 ;;^UTILITY(U,$J,358.3,6243,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6243,1,3,0)
 ;;=3^Recurrent & perst hematur w/ diffuse mesangiocap glomrlneph
 ;;^UTILITY(U,$J,358.3,6243,1,4,0)
 ;;=4^N02.5
 ;;^UTILITY(U,$J,358.3,6243,2)
 ;;=^5015516
 ;;^UTILITY(U,$J,358.3,6244,0)
 ;;=N02.6^^39^446^75
 ;;^UTILITY(U,$J,358.3,6244,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6244,1,3,0)
 ;;=3^Recurrent & perst hematur w/ dense deposit disease
 ;;^UTILITY(U,$J,358.3,6244,1,4,0)
 ;;=4^N02.6
 ;;^UTILITY(U,$J,358.3,6244,2)
 ;;=^5015517
 ;;^UTILITY(U,$J,358.3,6245,0)
 ;;=N02.7^^39^446^76
 ;;^UTILITY(U,$J,358.3,6245,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6245,1,3,0)
 ;;=3^Recurrent & perst hematur w/ diffuse crescentic glomrlneph
 ;;^UTILITY(U,$J,358.3,6245,1,4,0)
 ;;=4^N02.7
 ;;^UTILITY(U,$J,358.3,6245,2)
 ;;=^5015518
 ;;^UTILITY(U,$J,358.3,6246,0)
 ;;=N02.8^^39^446^81
 ;;^UTILITY(U,$J,358.3,6246,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6246,1,3,0)
 ;;=3^Recurrent & perst hematur w/ oth morphologic changes
 ;;^UTILITY(U,$J,358.3,6246,1,4,0)
 ;;=4^N02.8
 ;;^UTILITY(U,$J,358.3,6246,2)
 ;;=^5015519
 ;;^UTILITY(U,$J,358.3,6247,0)
 ;;=N02.9^^39^446^82
 ;;^UTILITY(U,$J,358.3,6247,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6247,1,3,0)
 ;;=3^Recurrent & perst hematur w/ unsp morphologic changes
 ;;^UTILITY(U,$J,358.3,6247,1,4,0)
 ;;=4^N02.9
 ;;^UTILITY(U,$J,358.3,6247,2)
 ;;=^5015520
 ;;^UTILITY(U,$J,358.3,6248,0)
 ;;=N03.0^^39^446^18
 ;;^UTILITY(U,$J,358.3,6248,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6248,1,3,0)
 ;;=3^Chr nephritic syndrome w/ minor glomerular abnormality
 ;;^UTILITY(U,$J,358.3,6248,1,4,0)
 ;;=4^N03.0
 ;;^UTILITY(U,$J,358.3,6248,2)
 ;;=^5015521
 ;;^UTILITY(U,$J,358.3,6249,0)
 ;;=N03.1^^39^446^17
 ;;^UTILITY(U,$J,358.3,6249,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6249,1,3,0)
 ;;=3^Chr nephritic syndrome w/ focal & seg glomerular lesions
 ;;^UTILITY(U,$J,358.3,6249,1,4,0)
 ;;=4^N03.1
 ;;^UTILITY(U,$J,358.3,6249,2)
 ;;=^5015522
 ;;^UTILITY(U,$J,358.3,6250,0)
 ;;=N03.2^^39^446^14
 ;;^UTILITY(U,$J,358.3,6250,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6250,1,3,0)
 ;;=3^Chr nephritic syndrome w/ diffuse membranous glomrlneph
 ;;^UTILITY(U,$J,358.3,6250,1,4,0)
 ;;=4^N03.2
 ;;^UTILITY(U,$J,358.3,6250,2)
 ;;=^5015523
 ;;^UTILITY(U,$J,358.3,6251,0)
 ;;=N03.3^^39^446^15
 ;;^UTILITY(U,$J,358.3,6251,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6251,1,3,0)
 ;;=3^Chr nephritic syndrome w/ diffuse mesangial prolif glomrlneph
 ;;^UTILITY(U,$J,358.3,6251,1,4,0)
 ;;=4^N03.3
 ;;^UTILITY(U,$J,358.3,6251,2)
 ;;=^5015524
 ;;^UTILITY(U,$J,358.3,6252,0)
 ;;=N03.4^^39^446^13
 ;;^UTILITY(U,$J,358.3,6252,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6252,1,3,0)
 ;;=3^Chr nephritic syndrome w/ diffuse endocaplry prolif glomrlneph
 ;;^UTILITY(U,$J,358.3,6252,1,4,0)
 ;;=4^N03.4
 ;;^UTILITY(U,$J,358.3,6252,2)
 ;;=^5015525
 ;;^UTILITY(U,$J,358.3,6253,0)
 ;;=N03.5^^39^446^16
 ;;^UTILITY(U,$J,358.3,6253,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6253,1,3,0)
 ;;=3^Chr nephritic syndrome w/ diffuse mesangiocap glomrlneph
 ;;^UTILITY(U,$J,358.3,6253,1,4,0)
 ;;=4^N03.5
 ;;^UTILITY(U,$J,358.3,6253,2)
 ;;=^5015526
 ;;^UTILITY(U,$J,358.3,6254,0)
 ;;=N03.6^^39^446^11
 ;;^UTILITY(U,$J,358.3,6254,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6254,1,3,0)
 ;;=3^Chr nephritic syndrome w/ dense deposit disease
 ;;^UTILITY(U,$J,358.3,6254,1,4,0)
 ;;=4^N03.6
 ;;^UTILITY(U,$J,358.3,6254,2)
 ;;=^5015527
 ;;^UTILITY(U,$J,358.3,6255,0)
 ;;=N03.7^^39^446^12
 ;;^UTILITY(U,$J,358.3,6255,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6255,1,3,0)
 ;;=3^Chr nephritic syndrome w/ diffuse crescentic glomrlneph
 ;;^UTILITY(U,$J,358.3,6255,1,4,0)
 ;;=4^N03.7
 ;;^UTILITY(U,$J,358.3,6255,2)
 ;;=^5015528
 ;;^UTILITY(U,$J,358.3,6256,0)
 ;;=N03.8^^39^446^19
 ;;^UTILITY(U,$J,358.3,6256,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6256,1,3,0)
 ;;=3^Chr nephritic syndrome w/ other morphologic changes
 ;;^UTILITY(U,$J,358.3,6256,1,4,0)
 ;;=4^N03.8
 ;;^UTILITY(U,$J,358.3,6256,2)
 ;;=^5015529
 ;;^UTILITY(U,$J,358.3,6257,0)
 ;;=N03.9^^39^446^20
 ;;^UTILITY(U,$J,358.3,6257,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6257,1,3,0)
 ;;=3^Chr nephritic syndrome w/ unsp morphologic changes
 ;;^UTILITY(U,$J,358.3,6257,1,4,0)
 ;;=4^N03.9
 ;;^UTILITY(U,$J,358.3,6257,2)
 ;;=^5015530
 ;;^UTILITY(U,$J,358.3,6258,0)
 ;;=N04.0^^39^446^60
 ;;^UTILITY(U,$J,358.3,6258,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6258,1,3,0)
 ;;=3^Nephrotic syndrome w/ minor glomerular abnormality
 ;;^UTILITY(U,$J,358.3,6258,1,4,0)
 ;;=4^N04.0
 ;;^UTILITY(U,$J,358.3,6258,2)
 ;;=^5015531
 ;;^UTILITY(U,$J,358.3,6259,0)
 ;;=N04.1^^39^446^59
 ;;^UTILITY(U,$J,358.3,6259,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6259,1,3,0)
 ;;=3^Nephrotic syndrome w/ focal & segmental glomerular lesions
 ;;^UTILITY(U,$J,358.3,6259,1,4,0)
 ;;=4^N04.1
 ;;^UTILITY(U,$J,358.3,6259,2)
 ;;=^5015532
 ;;^UTILITY(U,$J,358.3,6260,0)
 ;;=N04.2^^39^446^56
 ;;^UTILITY(U,$J,358.3,6260,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6260,1,3,0)
 ;;=3^Nephrotic syndrome w/ diffuse membranous glomerulonephritis
 ;;^UTILITY(U,$J,358.3,6260,1,4,0)
 ;;=4^N04.2
 ;;^UTILITY(U,$J,358.3,6260,2)
 ;;=^5015533
 ;;^UTILITY(U,$J,358.3,6261,0)
 ;;=N04.3^^39^446^57
 ;;^UTILITY(U,$J,358.3,6261,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6261,1,3,0)
 ;;=3^Nephrotic syndrome w/ diffuse mesangial prolif glomrlneph
 ;;^UTILITY(U,$J,358.3,6261,1,4,0)
 ;;=4^N04.3
 ;;^UTILITY(U,$J,358.3,6261,2)
 ;;=^5015534
 ;;^UTILITY(U,$J,358.3,6262,0)
 ;;=N04.4^^39^446^55
 ;;^UTILITY(U,$J,358.3,6262,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6262,1,3,0)
 ;;=3^Nephrotic syndrome w/ diffuse endocaplry prolif glomrlneph
 ;;^UTILITY(U,$J,358.3,6262,1,4,0)
 ;;=4^N04.4
 ;;^UTILITY(U,$J,358.3,6262,2)
 ;;=^5015535
 ;;^UTILITY(U,$J,358.3,6263,0)
 ;;=N04.5^^39^446^58
 ;;^UTILITY(U,$J,358.3,6263,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6263,1,3,0)
 ;;=3^Nephrotic syndrome w/ diffuse mesangiocapillary glomrlneph
